A5052570549- Chronic Myeloid Leukemia Treatments
- Chronic Lymphocytic Leukemia Research
- PI3K/AKT/mTOR signaling in cancer
- Pesticide Residue Analysis and Safety
- Analytical Methods in Pharmaceuticals
- Cancer Mechanisms and Therapy
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Hormonal Regulation and Hypertension
- Pharmacological Effects of Natural Compounds
- Gut microbiota and health
- Pharmacological Effects and Assays
- Lung Cancer Treatments and Mutations
Sichuan University
2023-2024
West China Hospital of Sichuan University
2024
Sichuan Cancer Hospital
2023
Air Force Medical University
2010
Xijing Hospital
2010
Objective To evaluate the effectiveness of oral probiotic supplements in patients undergoing immune checkpoint inhibitors (ICIs) for treatment advanced lung cancer. Methods This prospective real-world study enrolled with cancer who were receiving ICIs as part their treatment. The divided into 2 groups: Group OPS received along ICIs, while C did not. primary endpoint was progression-free survival (PFS). secondary outcome measure objective response rate (ORR). Results A total 253 included...
Background: Ultra-performance Liquid Chromatography-tandem Mass Spectrometry (UPLC-MS/MS) is widely used for concentration detection of many Tyrosine Kinase Inhibitors (TKIs), including afatinib, crizotinib, and osimertinib. In order to analyze whether pralsetinib takes effect in Rearranged during Transfection (RET)-positive patients with central nervous system metastasis, we aimed develop a method the concentrations human plasma Cerebrospinal Fluid (CSF) by UPLC-MS/MS. Methods: The was...
Rearranged during transfection (RET) had been reported to be a novel oncogenic driver in some solid tumors including non-small cell lung cancer (NSCLC), consequently pralsetinib (BLU-667) was have efficacy and low toxicity as RET-selective tyrosine kinase inhibitors (TKIs) for RET-positive NSCLC patients. The detection of the concentrations plasma cerebrospinal fluid (CSF) could served analyze whether takes effect NSCLCs with central nervous system metastasis. Ultra-performance liquid...